Savara Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.71
- Today's High:
- $3.83
- Open Price:
- $3.79
- 52W Low:
- $1.08
- 52W High:
- $4.21
- Prev. Close:
- $3.81
- Volume:
- 282041
Company Statistics
- Market Cap.:
- $515.01 million
- Book Value:
- 0.768
- Revenue TTM:
- $1000
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-28991000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -20.31%
- Return on Equity TTM:
- -39.75%
Company Profile
Savara Inc had its IPO on 2017-06-01 under the ticker symbol SVRA.
The company operates in the Healthcare sector and Biotechnology industry. Savara Inc has a staff strength of 28 employees.
Stock update
Shares of Savara Inc opened at $3.79 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.71 - $3.83, and closed at $3.75.
This is a -1.57% slip from the previous day's closing price.
A total volume of 282,041 shares were traded at the close of the day’s session.
In the last one week, shares of Savara Inc have slipped by -2.34%.
Savara Inc's Key Ratios
Savara Inc has a market cap of $515.01 million, indicating a price to book ratio of 1.4682 and a price to sales ratio of 131146.
In the last 12-months Savara Inc’s revenue was $1000 with a gross profit of $-28991000 and an EBITDA of $-44909000. The EBITDA ratio measures Savara Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Savara Inc’s operating margin was 0% while its return on assets stood at -20.31% with a return of equity of -39.75%.
In Q2, Savara Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Savara Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.27 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Savara Inc’s profitability.
Savara Inc stock is trading at a EV to sales ratio of 11.9082 and a EV to EBITDA ratio of -1.6744. Its price to sales ratio in the trailing 12-months stood at 131146.
Savara Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $119.83 million
- Total Liabilities
- $5.89 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $225000
- Dividend Payout Ratio
- 0%
Savara Inc ended 2024 with $119.83 million in total assets and $0 in total liabilities. Its intangible assets were valued at $119.83 million while shareholder equity stood at $87.72 million.
Savara Inc ended 2024 with $0 in deferred long-term liabilities, $5.89 million in other current liabilities, 116000.00 in common stock, $-360671000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $22.75 million and cash and short-term investments were $105.18 million. The company’s total short-term debt was $67,000 while long-term debt stood at $26.21 million.
Savara Inc’s total current assets stands at $107.90 million while long-term investments were $0 and short-term investments were $82.43 million. Its net receivables were $1.00 million compared to accounts payable of $2.50 million and inventory worth $1.56 million.
In 2024, Savara Inc's operating cash flow was $0 while its capital expenditure stood at $225000.
Comparatively, Savara Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.75
- 52-Week High
- $4.21
- 52-Week Low
- $1.08
- Analyst Target Price
- $5.5
Savara Inc stock is currently trading at $3.75 per share. It touched a 52-week high of $4.21 and a 52-week low of $4.21. Analysts tracking the stock have a 12-month average target price of $5.5.
Its 50-day moving average was $3.52 and 200-day moving average was $2.51 The short ratio stood at 4.43 indicating a short percent outstanding of 0%.
Around 196.1% of the company’s stock are held by insiders while 5882.7% are held by institutions.
Frequently Asked Questions About Savara Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.